In this webinar, we present a case study on Lynch syndrome (LS), a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia that typically manifests in the context of germline variants in DNA mismatched genes. 
To study whether other germline pathogenic variants of hereditary cancer genes are present in patients previously diagnosed with LS, the researchers analyzed a comprehensive panel of cancer-predisposing genes by NGS among 84 LS probands.

With this study as an example, we will illustrate how you can use your own data and public data to conduct translational research using 3 software solutions from QIAGEN.

This webinar will focus on the following elements:

• Data analysis – How you can efficiently retrieve and process FASTQ data with accurate variant interpretation using CLC Genomics Workbench
• Interpretation – How you can take a set of variants and rapidly assess sample variants for disease relevance and pathogenicity using QCI Interpret Translational
• Discovery – How you can combine results and contextualize variant biomarkers with other public datasets using QIAGEN Ingenuity Pathway Analysis (IPA)

 

Additional times available for these regions:

• Europe & Africa
• India
• North & South America

In this webinar, we present a case study on Lynch syndrome (LS), a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia that typically manifests in the context of germline variants in DNA mismatched genes. 
To study whether other germline pathogenic variants of hereditary cancer genes are present in patients previously diagnosed with LS, the researchers analyzed a comprehensive panel of cancer-predisposing genes by NGS among 84 LS probands.

With this study as an example, we will illustrate how you can use your own data and public data to conduct translational research using 3 software solutions from QIAGEN.

This webinar will focus on the following elements:

• Data analysis – How you can efficiently retrieve and process FASTQ data with accurate variant interpretation using CLC Genomics Workbench
• Interpretation – How you can take a set of variants and rapidly assess sample variants for disease relevance and pathogenicity using QCI Interpret Translational
• Discovery – How you can combine results and contextualize variant biomarkers with other public datasets using QIAGEN Ingenuity Pathway Analysis (IPA)

 

Additional times available for these regions:

• Asia & Australia
• India
• North & South America

In this webinar, we present a case study on Lynch syndrome (LS), a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia that typically manifests in the context of germline variants in DNA mismatched genes. 
To study whether other germline pathogenic variants of hereditary cancer genes are present in patients previously diagnosed with LS, the researchers analyzed a comprehensive panel of cancer-predisposing genes by NGS among 84 LS probands.

With this study as an example, we will illustrate how you can use your own data and public data to conduct translational research using 3 software solutions from QIAGEN.

This webinar will focus on the following elements:

• Data analysis – How you can efficiently retrieve and process FASTQ data with accurate variant interpretation using CLC Genomics Workbench
• Interpretation – How you can take a set of variants and rapidly assess sample variants for disease relevance and pathogenicity using QCI Interpret Translational
• Discovery – How you can combine results and contextualize variant biomarkers with other public datasets using QIAGEN Ingenuity Pathway Analysis (IPA)

 

Additional times available for these regions:

• Europe & Africa
• Asia & Australia
• North & South America

In this webinar, we present a case study on Lynch syndrome (LS), a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia that typically manifests in the context of germline variants in DNA mismatched genes. 
To study whether other germline pathogenic variants of hereditary cancer genes are present in patients previously diagnosed with LS, the researchers analyzed a comprehensive panel of cancer-predisposing genes by NGS among 84 LS probands.

With this study as an example, we will illustrate how you can use your own data and public data to conduct translational research using 3 software solutions from QIAGEN.

This webinar will focus on the following elements:

• Data analysis – How you can efficiently retrieve and process FASTQ data with accurate variant interpretation using CLC Genomics Workbench
• Interpretation – How you can take a set of variants and rapidly assess sample variants for disease relevance and pathogenicity using QCI Interpret Translational
• Discovery – How you can combine results and contextualize variant biomarkers with other public datasets using QIAGEN Ingenuity Pathway Analysis (IPA)

 

Additional times available for these regions:

• Europe & Africa
• Asia & Australia
• India

As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and accurate clinical interpretation of oncology diagnostic tests becomes even more pressing—especially among community hospital labs.

Standard sequencing panels are growing, drugs are covering more targets and pathways, and the expansion of the scientific and clinical literature has become exponential, presenting a significant challenge to laboratory directors and clinicians who need to understand the implications of the test results. Further, the implications of mutations can be applicable across many cancer types, but often are different based on the specific cancer type. 

In this webinar, we will discuss how community hospital labs can perform comprehensive genomic profiling faster and with greater accuracy and confidence using QIAGEN’s professional clinical interpretation services: QCI Precision Insights.

Attendees will learn:

• About the world-class team of molecular biologists and oncologists that power QCI Precision Insights
• How community hospital labs can get up-to-date and detailed disease-specific clinical insights and therapeutic options for each patient within minutes
• About use-cases and examples of clinical annotation in different diseases of varying specificity

 

Additional times available for these regions:

• Europe & Africa
• India
• North & South America

As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and accurate clinical interpretation of oncology diagnostic tests becomes even more pressing—especially among community hospital labs.

Standard sequencing panels are growing, drugs are covering more targets and pathways, and the expansion of the scientific and clinical literature has become exponential, presenting a significant challenge to laboratory directors and clinicians who need to understand the implications of the test results. Further, the implications of mutations can be applicable across many cancer types, but often are different based on the specific cancer type. 

In this webinar, we will discuss how community hospital labs can perform comprehensive genomic profiling faster and with greater accuracy and confidence using QIAGEN’s professional clinical interpretation services: QCI Precision Insights.

Attendees will learn:

• About the world-class team of molecular biologists and oncologists that power QCI Precision Insights
• How community hospital labs can get up-to-date and detailed disease-specific clinical insights and therapeutic options for each patient within minutes
• About use-cases and examples of clinical annotation in different diseases of varying specificity

 

Additional times available for these regions:

• Asia & Australia
• India
• North & South America

As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and accurate clinical interpretation of oncology diagnostic tests becomes even more pressing—especially among community hospital labs.

Standard sequencing panels are growing, drugs are covering more targets and pathways, and the expansion of the scientific and clinical literature has become exponential, presenting a significant challenge to laboratory directors and clinicians who need to understand the implications of the test results. Further, the implications of mutations can be applicable across many cancer types, but often are different based on the specific cancer type. 

In this webinar, we will discuss how community hospital labs can perform comprehensive genomic profiling faster and with greater accuracy and confidence using QIAGEN’s professional clinical interpretation services: QCI Precision Insights.

Attendees will learn:

• About the world-class team of molecular biologists and oncologists that power QCI Precision Insight
• How community hospital labs can get up-to-date and detailed disease-specific clinical insights and therapeutic options for each patient within minutes
• About use-cases and examples of clinical annotation in different diseases of varying specificity

 

Additional times available for these regions:

• Europe & Africa
• Asia & Australia
• North & South America

As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and accurate clinical interpretation of oncology diagnostic tests becomes even more pressing—especially among community hospital labs.

Standard sequencing panels are growing, drugs are covering more targets and pathways, and the expansion of the scientific and clinical literature has become exponential, presenting a significant challenge to laboratory directors and clinicians who need to understand the implications of the test results. Further, the implications of mutations can be applicable across many cancer types, but often are different based on the specific cancer type. 

In this webinar, we will discuss how community hospital labs can perform comprehensive genomic profiling faster and with greater accuracy and confidence using QIAGEN’s professional clinical interpretation services: QCI Precision Insights.

Attendees will learn:

• About the world-class team of molecular biologists and oncologists that power QCI Precision Insights
• How community hospital labs can get up-to-date and detailed disease-specific clinical insights and therapeutic options for each patient within minutes
• About use-cases and examples of clinical annotation in different diseases of varying specificity

 

Additional times available for these regions:

• Europe & Africa
• Asia & Australia
• India

Since the emergence of the COVID-19 pandemic, there has been an unprecedented interest in identifying ways to monitor and measure SARS-CoV-2 transmission. Many groups have focused on developing wastewater-based surveillance methods. By targeting wastewater, large populations of individuals can be monitored at different levels of scale in a passive, non-invasive and affordable way. By gathering information about fecal shedding of the virus in all persons, including symptomatic and asymptomatic individuals, viral trends in wastewater can be compared to trends observed from sequenced clinical specimens. The combination of clinical and wastewater-based sequencing can reveal the virus’s response to treatment, drugs and vaccines in large populations.

Wastewater epidemiology for SARS-CoV-2 has two aims: (1) to monitor the abundance of the virus in wastewater samples over time, and (2) to determine the relative amounts of mutations associated with variants of concern (VOC) that are of interest to healthcare professionals.

This webinar focuses on efforts to perform next-generation sequencing (NGS) of SARS-CoV-2 from wastewater using both targeted and whole genome amplification approaches. Dr. Smyth will discuss how she and her colleagues leveraged their prior experiences and knowledge to overcome challenges associated with varying viral concentrations and viral genome fragmentation (degradation) characteristic of wastewater samples so that NGS and analysis could be conducted successfully. In particular, the utility of a new solution, the QIAseq DIRECT SARS-CoV-2 Kit, will be evaluated, revealing how its ultrafast workflow and novel primer design for RNA-seq library preparation make it highly suited for the detection of emerging new SARS-CoV-2 variants. Finally, other bottlenecks and barriers to viral NGS-based wastewater analysis will be discussed in relation to potential future pandemics.

Copy number variant (CNV) analysis has been part of clinical diagnostics for almost two decades. With the evolution of genomic technologies for CNV detection, we have learned that CNVs can range in size from tens of bases to megabases and are an important source of both normal and pathogenic genomic variation. However, CNV interpretation requires collecting and evaluating multiple types of evidence from many sources, which has posed challenges for consistent, high quality clinical interpretation of CNVs. 

In this webinar, we will introduce a genomic variant analysis, interpretation and reporting solution that is being used by major labs and population health programs around the world. QCI Interpret is clinical decision support software that accelerates variant interpretation and reporting by automating curation workflows, dynamically computing variant classifications according to professional guidelines, and generating customized, patient-specific reports. The recent update of QCI Interpret further supports the interpretation and reporting of CNVs. Over 60,000 expert-curated CNV literature references have been added to QCI Interpret that the software can use among other evidence for interpretation, including generating auto-classifications of CNV pathogenicity with full transparency using the new ACMG/ClinGen CNV guidelines for hereditary workflows.  

Attend this webinar, and you will learn:

• About the new CNV features and content in QCI Interpret, including how the software computes CNV pathogenicity and improves handling of CNVs and splice variants at the imprecise exon- and precise breakpoint-levels
• How QCI Interpret helps you quickly evaluate your CNVs to determine if same/similar CNVs have been observed in clinical cases or as common genetic variants
• How QCI Interpret has new CNV classification functionalities following the new ACMG/ClinGen guidelines for the interpretation and reporting of constitutional CNVs

 

Additional times available for these regions:

• Europe & Africa
• India
• North & South America

Copy number variant (CNV) analysis has been part of clinical diagnostics for almost two decades. With the evolution of genomic technologies for CNV detection, we have learned that CNVs can range in size from tens of bases to megabases and are an important source of both normal and pathogenic genomic variation. However, CNV interpretation requires collecting and evaluating multiple types of evidence from many sources, which has posed challenges for consistent, high quality clinical interpretation of CNVs. 

In this webinar, we will introduce a genomic variant analysis, interpretation and reporting solution that is being used by major labs and population health programs around the world. QCI Interpret is clinical decision support software that accelerates variant interpretation and reporting by automating curation workflows, dynamically computing variant classifications according to professional guidelines, and generating customized, patient-specific reports. The recent update of QCI Interpret further supports the interpretation and reporting of CNVs. Over 60,000 expert-curated CNV literature references have been added to QCI Interpret that the software can use among other evidence for interpretation, including generating auto-classifications of CNV pathogenicity with full transparency using the new ACMG/ClinGen CNV guidelines for hereditary workflows.  

Attend this webinar, and you will learn:

• About the new CNV features and content in QCI Interpret, including how the software computes CNV pathogenicity and improves handling of CNVs and splice variants at the imprecise exon- and precise breakpoint-levels
• How QCI Interpret helps you quickly evaluate your CNVs to determine if same/similar CNVs have been observed in clinical cases or as common genetic variants
• How QCI Interpret has new CNV classification functionalities following the new ACMG/ClinGen guidelines for the interpretation and reporting of constitutional CNVs

 

Additional times available for these regions:

• Asia & Australia
• India
• North & South America

Copy number variant (CNV) analysis has been part of clinical diagnostics for almost two decades. With the evolution of genomic technologies for CNV detection, we have learned that CNVs can range in size from tens of bases to megabases and are an important source of both normal and pathogenic genomic variation. However, CNV interpretation requires collecting and evaluating multiple types of evidence from many sources, which has posed challenges for consistent, high quality clinical interpretation of CNVs. 

In this webinar, we will introduce a genomic variant analysis, interpretation and reporting solution that is being used by major labs and population health programs around the world. QCI Interpret is clinical decision support software that accelerates variant interpretation and reporting by automating curation workflows, dynamically computing variant classifications according to professional guidelines, and generating customized, patient-specific reports. The recent update of QCI Interpret further supports the interpretation and reporting of CNVs. Over 60,000 expert-curated CNV literature references have been added to QCI Interpret that the software can use among other evidence for interpretation, including generating auto-classifications of CNV pathogenicity with full transparency using the new ACMG/ClinGen CNV guidelines for hereditary workflows.  

Attend this webinar, and you will learn:

• About the new CNV features and content in QCI Interpret, including how the software computes CNV pathogenicity and improves handling of CNVs and splice variants at the imprecise exon- and precise breakpoint-levels
• How QCI Interpret helps you quickly evaluate your CNVs to determine if same/similar CNVs have been observed in clinical cases or as common genetic variants
• How QCI Interpret has new CNV classification functionalities following the new ACMG/ClinGen guidelines for the interpretation and reporting of constitutional CNVs

 

Additional times available for these regions:

• Europe & Africa
• Asia & Australia
• North & South America

Copy number variant (CNV) analysis has been part of clinical diagnostics for almost two decades. With the evolution of genomic technologies for CNV detection, we have learned that CNVs can range in size from tens of bases to megabases and are an important source of both normal and pathogenic genomic variation. However, CNV interpretation requires collecting and evaluating multiple types of evidence from many sources, which has posed challenges for consistent, high quality clinical interpretation of CNVs. 

In this webinar, we will introduce a genomic variant analysis, interpretation and reporting solution that is being used by major labs and population health programs around the world. QCI Interpret is clinical decision support software that accelerates variant interpretation and reporting by automating curation workflows, dynamically computing variant classifications according to professional guidelines, and generating customized, patient-specific reports. The recent update of QCI Interpret further supports the interpretation and reporting of CNVs. Over 60,000 expert-curated CNV literature references have been added to QCI Interpret that the software can use among other evidence for interpretation, including generating auto-classifications of CNV pathogenicity with full transparency using the new ACMG/ClinGen CNV guidelines for hereditary workflows.  

Attend this webinar, and you will learn:

• About the new CNV features and content in QCI Interpret, including how the software computes CNV pathogenicity and improves handling of CNVs and splice variants at the imprecise exon- and precise breakpoint-levels
• How QCI Interpret helps you quickly evaluate your CNVs to determine if same/similar CNVs have been observed in clinical cases or as common genetic variants
• How QCI Interpret has new CNV classification functionalities following the new ACMG/ClinGen guidelines for the interpretation and reporting of constitutional CNVs

 

Additional times available for these regions:

• Europe & Africa
• Asia & Australia
• India